CTOs on the Move

The Mighty

www.themighty.com

 
The Mighty is a digital health community created to empower and connect people facing health challenges and disabilities. We have over 2.5 million registered users and are adding a new one every 20 seconds. Our stories and videos are viewed and shared more than 90 million times a month. But those are just stats. This experience from a community member is what we`re really after: “How is it that I read an essay on The Mighty and it is the only place in the world where I feel truly understood? Time and time again you speak to me through your ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.themighty.com
  • 210 N Glenoaks Boulevard Suite C
    Burbank, CA USA 91502
  • Phone: 213.379.2407

Executives

Name Title Contact Details
Peter Wang
 Chief Technology Officer Profile

Similar Companies

Capitol Drugs

Capitol Drugs is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Sherman Oaks, CA. To find more information about Capitol Drugs, please visit www.capitoldrugs.com

Plume

We provide gender-affirming hormone therapy via telehealth for the trans-community across the United States. Based in Denver, CO, Plume is trans-founded and has received backing from top-tier venture capital. Our mission is to create deeply affirming direct-to-consumer pharmaceutical services for the trans and broader queer community. We are currently hiring talented, inspired and mission-aligned individuals.

Century Park Associates

Century Park Associates is a Chattanooga, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BetterMynd

BetterMynd is an online therapy platform for college students that aims to increase accessibility to mental health services and reduce stigma surrounding mental distress in young adults.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.